1. Home
  2. Analysis

Erosive duodenitis and drugs of ingredients of nitroglycerin (a real world drug study)


Summary:

Erosive duodenitis is found among people who take drugs with ingredients of nitroglycerin, especially for people who are male, 60+ old , have been taking the drugs for 10+ years. This phase IV clinical study is created by eHealthMe based on reports of 77,156 people who have side effects when taking drugs with ingredients of nitroglycerin from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Gonitro, Minitran, Nitro iv, Nitro-bid, Nitro-dur, Nitroglycerin, Nitroglycerin in dextrose 5%, Nitrol, Nitrolingual, Nitrolingual pumpspray, Nitromist, Nitronal, Nitrostat, Transderm-nitro, Tridil.

On Jul, 02, 2026

77,156 people reported to have side effects when taking drugs with ingredients of nitroglycerin.
Among them, 12 people (0.02%) have Erosive duodenitis

What is Erosive duodenitis?

Erosive duodenitis (a condition that affects the wall of the small intestine) is found to be associated with 183 drugs and 287 conditions by eHealthMe. Check the latest studies of Erosive duodenitis.

Number of reports submitted per year:

Could drugs with ingredients of nitroglycerin cause Erosive duodenitis?

Time on drugs with ingredients of nitroglycerin when people have Erosive duodenitis *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 100 %

Gender of people who have Erosive duodenitis when taking drugs with ingredients of nitroglycerin *:

  • female: 16.67 %
  • male: 83.33 %

Age of people who have Erosive duodenitis when taking drugs with ingredients of nitroglycerin *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 8.33 %
  • 60+: 91.67 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Platelet Aggregation Inhibition: 2 people, 16.67%
  2. Muscle Contracture (a permanent shortening of a muscle): 2 people, 16.67%
  3. Type 2 Diabetes: 1 person, 8.33%
  4. Tumor: 1 person, 8.33%
  5. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 8.33%
  6. High Blood Pressure: 1 person, 8.33%
  7. High Blood Cholesterol: 1 person, 8.33%
  8. Diabetes: 1 person, 8.33%
  9. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 8.33%
  10. Acute Myocardial Infarction (acute heart attack): 1 person, 8.33%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Aspirin: 9 people, 75.00%
  2. Ibuprofen: 6 people, 50.00%
  3. Allopurinol: 5 people, 41.67%
  4. Vioxx: 5 people, 41.67%
  5. Ambien: 5 people, 41.67%
  6. Lansoprazole: 4 people, 33.33%
  7. Gemfibrozil: 4 people, 33.33%
  8. Isosorbide Mononitrate: 4 people, 33.33%
  9. Levothyroxine Sodium: 4 people, 33.33%
  10. Lisinopril: 4 people, 33.33%

Other side effects people have besides Erosive duodenitis *:

You may use this to check any potential undetected side effects.

  1. Cardiac Failure Congestive: 5 people, 41.67%
  2. Diarrhea: 5 people, 41.67%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 41.67%
  4. Supraventricular Extrasystoles (premature electrical impulse in the heart, generated above the level of the ventricle): 4 people, 33.33%
  5. Hypochromasia (an anaemic condition): 4 people, 33.33%
  6. Anaemia (lack of blood): 4 people, 33.33%
  7. Blood Chloride Decreased: 4 people, 33.33%
  8. Blood Glucose Increased: 4 people, 33.33%
  9. Blood Pressure Abnormal: 4 people, 33.33%
  10. Dehydration (dryness resulting from the removal of water): 4 people, 33.33%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of nitroglycerin, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on nitroglycerin. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.